Showing 1991-2000 of 2050 results for "".
- Fluoride Can Cause Degenerative Eye Diseases, Study Showshttps://modernod.com/news/fluoride-can-cause-degenerative-eye-diseases-study-shows/2476388/Fluoride contributes to degenerative eye diseases such as cataracts, age related macular degeneration (AMD) and glaucoma, reports DT Waugh in the
- Clinical Trials Show Safety and Efficacy of Inveltys for BID Treatment of Postoperative Inflammation and Painhttps://modernod.com/news/clinical-trials-show-safety-and-efficacy-of-kala-pharmaceuticals-inveltys-for-bid-treatment-of-postoperative-inflammation-and-pain/2476380/Kala Pharmaceuticals announced publication of two multicenter, randomized, double-masked, vehicle-controlled clinical trials of Inveltys (loteprednol etabonate ophthalmic suspension 1%) for treatment of inflammation and pain following cataract surgery. Inveltys, which utilizes AMPPLIFY D
- Dompé Receives Industry Innovation Award for Oxervate Eye Drops for Neurotrophic Keratitishttps://modernod.com/news/dompe-receives-industry-innovation-award-for-oxervate-eye-drops-for-neurotrophic-keratitis/2476372/Dompé Farmaceutici S.p.A and Dompé US Inc. announced that the National Organization for Rare Disorders (NORD) has awarded them the 2019 Industry Innovation Award for Oxervate. The Rare Impact Awards celebrate people, organizations, and innovators making exceptional contributions benefiting rare d
- Cataract-Surgery Adjuncts Improve Vision in Diabetic Macular Edemahttps://modernod.com/news/cataract-surgery-adjuncts-improve-vision-in-diabetic-macular-edema/2476367/Both intravitreous bevacizumab (BVB) and triamcinolone acetate (TA) improve outcomes when given as an adjunct to cataract surgery in patients with diabetic macular edema (DME), a new randomized controlled trial shows., according to a Reuters r
- Pharmaceutical Executives Field Questions at US Senate Hearing Over Drug Pricinghttps://modernod.com/news/pharmaceutical-executives-field-questions-at-us-senate-hearing-over-drug-pricing/2476258/CEOs and senior executives from AbbVie, AstraZeneca, Bristol-Myers Squibb, Merck & Co., Pfizer, Sanofi, and Johnson & Johnson appeared before the US Senate Finance Committee on Tuesday to testify about the high cost of drugs in the country. The executives, who continued to blame pharmacy
- EyeBrain Medical and IDOC Announce Partnership to Bring Neurolens to IDOC Independent Optometristshttps://modernod.com/news/eyebrain-medical-and-idoc-announce-partnership-to-bring-neurolens-to-idoc-independent-optometrists/2476270/IDOC and eyeBrain Medical announced a multiyear partnership to bring neurolens prescription lenses to all IDOC members across the United States. Neurolenses are the first and only prescription lenses that add a contoured prism to bring the eyes into alignment. Contoured prisms have been shown in
- Health Burden of Glaucoma Has Risen Worldwidehttps://modernod.com/news/health-burden-of-glaucoma-has-risen-worldwide/2476271/The health burden of glaucoma has continuously increased around the globe in the past 25 years, according to an Acta Opthalmologica study. Higher burdens were associat
- Bruder Introduces Hygienic Eyelid Solutionhttps://modernod.com/news/bruder-introduces-hygienic-eyelid-solution/2476280/Bruder Healthcare announced the immediate availability of Bruder Hygienic Eyelid Solution, a 0.2% pure hypochlorous acid solution that’s safe for daily, long-term use. This solution contains no alcohol, oil, sulfates,
- USPSTF Reaffirms Advice on Prevention of Gonococcal Eye Infections in Newbornshttps://modernod.com/news/uspstf-reaffirms-advice-on-prevention-of-gonococcal-eye-infections-in-newborns/2476334/The U.S. Preventive Services Task Force (USPSTF) continues to recommend that all newborns be treated with a topical antibiotic ointment to prevent gonococcal eye infections, according to a Reuters report. This “A” recom
- Bausch Health Reduces Debt By Additional $100 Millionhttps://modernod.com/news/bausch-health-reduces-debt-by-additional-100-million/2476341/Bausch Health Companies, the parent company of Bausch + Lomb, announced it has paid down an additional $100 million of its senior secured term loans using cash generated from operations. “As Bausch Health pivots to offense in 2019, we continue to remain